Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Immunogenicity of SB5 vs Humira in Healthy Subjects
NCT02144714Phase 1Completed
- Sponsor
- Samsung Bioepis
- Start
- May 2014
- Primary completion
- Sep 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of adalimumab in rheumatoid arthritis (RA) (3 arms), sponsored by Samsung Bioepis. Primary endpoints: Area Under the Concentration-time Curve From Time Zero to Infinity, Maximum Serum Concentration and 1 more. Started May 2014; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02144714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02144714.